Gujarat Pollution Board Orders Closure Direction for Sudeep Pharma Unit
Sudeep Pharma Limited has disclosed a regulatory setback after the Gujarat Pollution Control Board issued closure directions for a manufacturing unit operated by its subsidiary, Sudeep Nutrition Private Limited, at Poicha (Rania) in Vadodara district. The action relates to environmental compliance requirements under the Water (Prevention and Control of Pollution) Act, 1974.
The affected facility is located at Plot No. 500/24/1, 3, 4 and 5, Poicha (Rania), Taluka Savli, Vadodara. The closure direction was issued under Section 33A of the Water Act, which gives pollution control authorities powers to issue directions, including restrictions on industrial operations.
An important detail is that Sudeep Pharma says it viewed the closure directions letter on the GPCB portal, but the physical copy of the notice had not yet been received. The company is examining the contents and taking corrective action.
The observations originated from a GPCB inspection conducted on November 6, 2026. The inspection identified three areas of non compliance involving wastewater collection, water discharge and raw material storage at the subsidiary facility.
The first observation concerns a damaged wastewater collection pipeline. The company has been asked to repair the pipeline to address the infrastructure problem and ensure that wastewater is collected and handled appropriately.
The second issue relates to water discharge. GPCB has directed the unit to ensure that only treated water is discharged into the internal storm water drainage system. This requirement is important because untreated industrial wastewater can contaminate drainage networks and surrounding water resources.
The third observation concerns raw materials stored in the open. The authority has asked the company to provide a covered shed for certain raw materials to improve storage conditions and prevent exposure to environmental elements.
These observations relate to specific infrastructure and environmental management requirements. The company will need to complete the necessary repairs and demonstrate compliance with the applicable conditions before seeking restoration of normal operations at the affected facility.
GPCB has also asked the company to provide a bank guarantee of ₹1.50 lakh, valid for one year, as compliance assurance under its bank guarantee policy at the time of revocation. This is a regulatory compliance requirement and should not be confused with a tax penalty or a confirmed financial fine.
Sudeep Pharma has stated that corrective actions are already underway. The company is examining the regulatory directions and working to address the identified issues, with the objective of restoring normal operations at the earliest.
The scope of the action is limited to the manufacturing unit of Sudeep Nutrition Private Limited. Sudeep Pharma has specifically stated that manufacturing activities at all its other manufacturing units will continue operating.
The company also does not anticipate a financial impact from the development. However, the actual operational effect on the subsidiary facility will depend on the time required to complete the corrective work and obtain regulatory clearance.
Sudeep Nutrition is part of a wider business that manufactures ingredients and products for pharmaceutical, food and nutrition applications. Sudeep Pharma operates in areas including mineral based ingredients, pharmaceutical excipients, food ingredients and nutritional products.
Its products serve customers in pharmaceutical manufacturing, food processing and nutrition markets. Manufacturing quality, regulatory compliance and consistent supply are important because customers depend on these ingredients for their own production processes.
The latest financial results provide context for the regulatory development. Sudeep Pharma reported consolidated revenue of ₹196.70 crore in Q2 FY27, compared with ₹162.67 crore in the corresponding quarter of the previous year, representing growth of approximately 20.9%.
Consolidated EBITDA increased to ₹79.22 crore from ₹65.63 crore, while EBITDA margin improved to approximately 37.23% from 34.10%. The improvement indicates stronger operating profitability alongside revenue growth.
Net profit increased to ₹51.45 crore from ₹45.75 crore, representing growth of approximately 12.5%. Earnings per share stood at ₹4.59 compared with ₹4.20 in the year ago quarter.
These results show that the company had reported growth in revenue, operating profit and net profit before the closure direction became a new regulatory issue. The financial performance of the affected subsidiary facility has not been separately quantified in the closure disclosure.
Another important development is the new greenfield manufacturing facility at Nandesari, Gujarat. The Gujarat Food and Drug Control Administration approved the facility on October 26, 2026, with an installed annual capacity of 51,200 metric tonnes for pharmaceutical, food and nutrition products.
The Nandesari facility could strengthen the company manufacturing network and provide additional capacity for future demand. However, its installed capacity should not be treated as actual production or revenue. Utilisation, customer approvals, product mix and commercial orders will determine the financial contribution.
The presence of other operational manufacturing facilities provides some protection against a disruption limited to the Poicha unit. Nevertheless, investors need to understand which products are manufactured at the affected site and whether production can be transferred to other facilities without additional costs or delays.
For customers, the important issues are supply continuity, product availability and the ability of the company to meet delivery commitments. Any prolonged restriction at Poicha could require changes to manufacturing schedules, inventory planning and logistics, although Sudeep Pharma has not reported any such disruption.
Investors should monitor completion of the wastewater pipeline repair, confirmation that only treated water is being discharged, construction of the covered raw material storage area and submission of the required bank guarantee. The most important regulatory milestone will be formal clearance or revocation of the closure direction by GPCB.
Sudeep Pharma has reported no anticipated financial impact and confirmed that its other manufacturing facilities remain operational. The immediate concern is the time required to resolve the environmental compliance issues at Poicha and secure regulatory clearance. The next company update will help establish whether the matter remains a limited facility level disruption or begins affecting production, customer deliveries and financial performance.